The MYTI project has delivered essential technical and strategic results that significantly advance the myokinetic interface toward clinical and commercial viability. Building on the achievements described in the previous sections, the project has consolidated the scientific, technological, and translational foundations needed for the next steps in bringing this disruptive human–machine interface to end users.
The long-term impact of MYTI lies in enabling a new class of human-machine-interfaces for the control of assistive devices that are intuitive, minimally invasive, and capable of providing reliable, multi-Degree of Freedom control. By overcoming key technical barriers that previously limited the myokinetic interface to short-term applications, the project opens the path toward chronic implantation and meaningful real-life use by individuals with limb loss or, potentially, other types of motor disabilities.
Moreover, a central component of the project broader impact was the strengthening of the team entrepreneurial and translational competences. To fulfill this commitment, the MYTI team attended intensive programs designed to introduce young researchers and innovators to the fundamental aspects of technology entrepreneurship. The latter aimed to equip participants with the skills needed to transform scientific ideas into viable business ventures by covering topics such as opportunity recognition, market validation, business modelling, financial strategy, and investor communication. Regarding IP protection, a patent application was submitted and is currently under evaluation, which represents a background patent for the technology developed. All technical activities in the project were conducted in alignment with the Medical Device Regulation (MDR) and relevant international standards governing medical devices and implantable components. This compliance ensures that the results generated by MYTI fit seamlessly into the future regulatory pathway toward CE marking and clinical deployment. In the future, activities will aim at completing the certification process and conducting extended clinical trials for the technology safety and efficacy validation, other than pursuing a continued refinement and testing of implantation protocols, aiming to optimize surgical workflow, patient comfort, and system performance, in continuous collaboration with expert clinicians. Not least, to extension of the myokinetic interface to additional anatomical regions or applications, increasing its commercial attractiveness and patient impact, will be investigated.
These results collectively position the myokinetic interface closer to real-world clinical adoption and create a solid foundation for the next translational phase.
